International Society of Liquid Biopsy/X
Apr 18, 2025, 23:42
Liquid Biopsy at Baseline Adds Prognostic and Predictive Value in mCRC – International Society of Liquid Biopsy
International Society of Liquid Biopsy shared a post on X:
“Liquid Biopsy at Baseline Adds Prognostic and Predictive Value in mCRC
From the FIRE-4 (AIO-KRK-0114) Study — Stintzing et al., Journal of Clinical Oncology 2025
Key Highlights:
- 13% of RASwt patients by tissue were RASmut on liquid biopsy (LB)
- RASmut and BRAFV600E mutations detected by LB were linked to significantly shorter PFS and OS
- Patients with RASmut had better outcomes with switch maintenance to bevacizumab vs continued cetuximab
- 15.3% of initially RASwt patients converted to RASmut at progression—more frequent with prolonged cetuximab
- LB detects heterogeneity and emerging resistance, reinforcing its clinical utility
This study confirms LB’s role in improving real-time decision-making in mCRC and suggests it may outperform tissue testing in mutation detection at baseline.”
Authors: Sebastian Stintzing et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 20:54
Apr 23, 2025, 20:29
Apr 23, 2025, 19:57
Apr 23, 2025, 17:10
Apr 23, 2025, 16:51